Page Title
Clinical Trial Finder
Anti-Infective Closed to Enrollment
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study (Novartis CTBM100C2401E1)
The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
Eligibility
See other primary eligibility criteria for more information.
-
Age:
6 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
25 to 75%
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Only participants from core study CTBM100C2401 are eligible.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
48 weeks -
Number of Study Visits:
8
Additional Information
-
Phase: ?more info
Phase Four/Post-Approval -
Study Sponsor: ?more info
Novartis -
Study Drugs:
Study Sites
-
Closed to Enrollment
Ohio
Children's Hospital Medical Center of Akron, Akron, OH 44308
-
Closed to Enrollment
South Carolina
Medical University of South Carolina, Charleston, SC 29425
-
Closed to Enrollment
Texas
Baylor College of Medicine, Houston, TX 77030
Eligibility
See other primary eligibility criteria for more information.
-
Age:
6 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
25 to 75% -
Pseudomonas Status:
Positive Respiratory Cultures Required
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Only participants from core study CTBM100C2401 are eligible.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More